Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | 0.00% | 0.00% | -53.49% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 7.989 | 6.311 | 14.24 | 20.3 | 14.48 | 13.13 |
Enterprise Value (EV) 1 | 43.49 | 43.65 | 49.92 | 54.63 | 50.65 | 48.9 |
P/E ratio | -3.75 x | -7.04 x | 4.95 x | -8.49 x | -5.97 x | -3.28 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 2.2 x | 0.91 x | 0.68 x | 0.69 x | 0.36 x | 0.36 x |
EV / Revenue | 12 x | 6.3 x | 2.39 x | 1.87 x | 1.25 x | 1.33 x |
EV / EBITDA | 25.1 x | 16.5 x | 10.1 x | 54.4 x | 33.6 x | -6.7 x |
EV / FCF | 44.9 x | 53.4 x | 18.7 x | 89.1 x | -75 x | -20 x |
FCF Yield | 2.23% | 1.87% | 5.36% | 1.12% | -1.33% | -5.01% |
Price to Book | 19.8 x | -30.8 x | 5.4 x | 9.02 x | 81.9 x | -3.53 x |
Nbr of stocks (in thousands) | 2,663 | 2,744 | 2,687 | 2,900 | 3,055 | 3,055 |
Reference price 2 | 3.000 | 2.300 | 5.300 | 7.000 | 4.740 | 4.300 |
Announcement Date | 4/16/19 | 7/10/20 | 3/31/21 | 8/26/22 | 6/30/23 | 4/16/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 3.623 | 6.93 | 20.93 | 29.29 | 40.6 | 36.78 |
EBITDA 1 | 1.733 | 2.652 | 4.955 | 1.004 | 1.506 | -7.294 |
EBIT 1 | 0.4749 | 1.301 | 3.375 | -0.729 | -0.2866 | -8.96 |
Operating Margin | 13.11% | 18.77% | 16.13% | -2.49% | -0.71% | -24.36% |
Earnings before Tax (EBT) 1 | -2.007 | -0.868 | 2.962 | -2.241 | -2.396 | -3.971 |
Net income 1 | -1.992 | -0.8616 | 2.956 | -2.252 | -2.396 | -3.971 |
Net margin | -54.98% | -12.43% | 14.12% | -7.69% | -5.9% | -10.8% |
EPS 2 | -0.8000 | -0.3268 | 1.070 | -0.8243 | -0.7943 | -1.310 |
Free Cash Flow 1 | 0.9689 | 0.8172 | 2.675 | 0.6131 | -0.6754 | -2.449 |
FCF margin | 26.74% | 11.79% | 12.78% | 2.09% | -1.66% | -6.66% |
FCF Conversion (EBITDA) | 55.9% | 30.81% | 53.99% | 61.05% | - | - |
FCF Conversion (Net income) | - | - | 90.52% | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/16/19 | 7/10/20 | 3/31/21 | 8/26/22 | 6/30/23 | 4/16/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 35.5 | 37.3 | 35.7 | 34.3 | 36.2 | 35.8 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 20.48 x | 14.08 x | 7.201 x | 34.18 x | 24.02 x | -4.903 x |
Free Cash Flow 1 | 0.97 | 0.82 | 2.68 | 0.61 | -0.68 | -2.45 |
ROE (net income / shareholders' equity) | -123% | -128% | 165% | -70.9% | -118% | 395% |
ROA (Net income/ Total Assets) | 0.78% | 2.08% | 4.92% | -0.98% | -0.4% | -13.5% |
Assets 1 | -256.8 | -41.43 | 60.12 | 229.5 | 598.1 | 29.48 |
Book Value Per Share 2 | 0.1500 | -0.0700 | 0.9800 | 0.7800 | 0.0600 | -1.220 |
Cash Flow per Share 2 | 0.4100 | 0.2300 | 1.330 | 1.310 | 0.4600 | 0.4800 |
Capex | - | - | 1.12 | - | - | - |
Capex / Sales | - | - | 5.35% | - | - | - |
Announcement Date | 4/16/19 | 7/10/20 | 3/31/21 | 8/26/22 | 6/30/23 | 4/16/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-53.49% | 6.13M | |
-14.92% | 84.68B | |
+13.30% | 81.12B | |
+11.62% | 29.59B | |
-12.71% | 16.73B | |
-3.06% | 16.36B | |
-2.63% | 14.92B | |
-31.40% | 11.77B | |
-1.42% | 11.72B | |
+27.44% | 11.71B |
- Stock Market
- Equities
- GBCS Stock
- Financials Selectis Health, Inc.